<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202265</url>
  </required_header>
  <id_info>
    <org_study_id>48612013</org_study_id>
    <nct_id>NCT02202265</nct_id>
  </id_info>
  <brief_title>Polymorphisms in CD36 and STAT3 Genes and Different Dietary Interventions Among Patients With Coronary Artery Disease</brief_title>
  <acronym>GENUTRI</acronym>
  <official_title>Effect of Polymorphisms in CD36 and STAT3 Genes on Different Dietary Interventions Among Patients With Coronary Artery Disease: a Randomized Clinical Trial With a Nutrigenetic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiologia do Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Cardiologia do Rio Grande do Sul</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Cardiovascular diseases are the major health problem worldwide and the&#xD;
      understanding of genetic contributions on the development of cardiovascular diseases is&#xD;
      increasing significantly. The CD36 is a protein associated with uptake of oxidized forms of&#xD;
      LDL and the single nucleotide polymorphism (SNP) rs1761667 A/G in the CD36 gene is correlated&#xD;
      with increased consumption of total fat. The transcription factor STAT3 is released during&#xD;
      the inflammatory acute phase response and the SNP rs8069645 G/A in the STAT3 gene is&#xD;
      associated with abdominal obesity and higher intake of saturated fat. Studies have been shown&#xD;
      the benefits of the Mediterranean diet in secondary prevention of cardiovascular disease and&#xD;
      these dietary patterns have been often studied with nutrigenetic approach; these studies,&#xD;
      however, are often limited to European populations, making it difficult to generalize to&#xD;
      different populations.&#xD;
&#xD;
      Hypothesis: Different dietary approaches may similarly influence in modifying metabolic,&#xD;
      inflammatory and anthropometric profile, especially among patients with coronary arterial&#xD;
      disease (CAD). The genetic interaction with environmental factors such as the nutrient&#xD;
      intake, and the prescription of a different diet according to individual genotype, could&#xD;
      influence the development and/or the treatment of cardiovascular diseases.&#xD;
&#xD;
      Objective: To evaluate the effect of three dietary approaches on metabolic, inflammatory and&#xD;
      anthropometric profile in patients with CAD and possible interactions with polymorphisms in&#xD;
      CD36 and STAT3 genes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized clinical trial with a nutrigenetic approach among patients ≥ 40 years diagnosed&#xD;
      with CAD. Randomization will be made in blocks from a list of random numbers generated by&#xD;
      site www.randomization.org (sealed opaque envelopes). A questionnaire with demographic and&#xD;
      clinical data will be applied; systolic and diastolic blood pressure, waist, hip and neck&#xD;
      circumferences, height and weight will be assessed. Nutrients intake will be assessed through&#xD;
      a food diary. Laboratory evaluation will consist of lipid profile (LDL-cholesterol,&#xD;
      HDL-cholesterol and total cholesterol, serum triglycerides), glycemic profile (fasting plasma&#xD;
      glucose, glycated hemoglobin) and inflammatory profile (high-sensitivity C-reactive protein,&#xD;
      fibrinogen, TNF-alpha, interleukin-6 and interleukin-10). Genotyping will be made by TaqMan&#xD;
      SNP Genotyping Assay®. Patients will be randomized in three groups: Group 1 Intervention&#xD;
      [Supplementation with nuts (SN)]: standard dietary guidelines + 30g of nuts a day; Group 2&#xD;
      Intervention [Supplementation with olive oil (SAO)]: standard dietary guidelines + 30ml of&#xD;
      olive oil a day; Group 3 [Control diet (CO)]: standard dietary guidelines. Patients will be&#xD;
      followed for three months (12 weeks) and the primary endpoint will be the change in&#xD;
      LDL-cholesterol. The follow-up visits will be made at 30 days, 60 days and 90 days (final&#xD;
      visit).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 17, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL</measure>
    <time_frame>twelve weeks</time_frame>
    <description>LDL-cholesterol, in mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TC</measure>
    <time_frame>twelve weeks</time_frame>
    <description>total cholesterol (TC), in mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NHDL</measure>
    <time_frame>twelve weeks</time_frame>
    <description>non-HDL-cholesterol, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL</measure>
    <time_frame>twelve weeks</time_frame>
    <description>HDL-cholesterol, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG</measure>
    <time_frame>twelve weeks</time_frame>
    <description>serum triglyceride, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TyG index</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Triglycerides/fasting glucose index, calculated according to (fasting triglycerides [mg/dL] x fasting glucose [mg/dL])/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>twelve weeks</time_frame>
    <description>glycated hemoglobin (HbA1C), in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FG</measure>
    <time_frame>twelve weeks</time_frame>
    <description>fasting glucose, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>twelve weeks</time_frame>
    <description>serum insulin, in UI/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), calculated according to fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory profile</measure>
    <time_frame>twelve weeks</time_frame>
    <description>CRP-us, in mg/dL; IL-6, in mg/dL; IL-10, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BW</measure>
    <time_frame>twelve weeks</time_frame>
    <description>body weight, in kg;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>twelve weeks</time_frame>
    <description>body mass index (BMI), in kg/m2, calculated according to weight (kg)/height*height (m)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WC</measure>
    <time_frame>twelve weeks</time_frame>
    <description>waist circumference, in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NC</measure>
    <time_frame>twelve weeks</time_frame>
    <description>neck circumference, in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LAP index</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Lipid Accumulation Product Index (in cm.mmol.l), calculated for men: men (waist circumference [WC] - 65) x triglycerides (TG), and women (WC - 58) x TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAAT index</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Deep-Abdominal-Adipose-Tissue Index (in cm2), calculated for men (- 382.9 + [1.09 x weight] + [6.04 x waist circumference (WC)] + [- 2.29 x body mass index (BMI)]) and women (- 278 + [- 0.86 x weight] + [5.19 x WC])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAI index</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Visceral Adiposity Index (log), calculated for men (waist circumference (WC)/[39 + (1.88 x body mass index (BMI)) x (triglycerides (TG)/1.03) x (1.31/HDL)]) and women (WC/[36.58 + (1.89 x BMI) x (TG/0.81) x (1.53/HDL)])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFA</measure>
    <time_frame>twelve weeks</time_frame>
    <description>plasma fatty acids, in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mon</measure>
    <time_frame>twelve weeks</time_frame>
    <description>plasma monocytes, in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rs1761667 G&gt;A</measure>
    <time_frame>baseline</time_frame>
    <description>Polymorphism rs1761667 G&gt;A in the CD36 gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rs8069645 A&gt;G</measure>
    <time_frame>baseline</time_frame>
    <description>Polymorphism rs8069645 A&gt;G in the STAT3 gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interaction diet * genotype</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Interaction between dietary intervention, rs1761667 and rs8069645</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Control diet (standard dietary)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a control diet based on standard dietary guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olive oil (30ml a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a control diet based on standard dietary guidelines + 30ml of olive oil a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nuts (30g a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a control diet based on standard dietary guidelines plus 30g of nuts a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Olive oil</intervention_name>
    <description>30ml a day of olive oil</description>
    <arm_group_label>Olive oil (30ml a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nuts</intervention_name>
    <description>30g a day of nuts</description>
    <arm_group_label>Nuts (30g a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control diet</intervention_name>
    <description>Diet based on standard guidelines</description>
    <arm_group_label>Control diet (standard dietary)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with coronary arterial disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric disease;&#xD;
&#xD;
          -  Morbid obesity (BMI ≥ 40mg/m2);&#xD;
&#xD;
          -  Expectancy of life less than 6 months;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Renal failure (in dialysis);&#xD;
&#xD;
          -  Congestive heart failure;&#xD;
&#xD;
          -  Prior organ transplantation;&#xD;
&#xD;
          -  Patients in wheelchair;&#xD;
&#xD;
          -  Use of vitamin/nutritional supplements;&#xD;
&#xD;
          -  Chronic use of non steroidal anti-inflammatory drugs;&#xD;
&#xD;
          -  Participation in another experimental study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aline Marcadenti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Cardiologia/Fundação Universitária de Cardiologia (IC/FUC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vera L Portal, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia/Fundação Universitária de Cardiologia (IC/FUC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melissa M Markoski, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia/Fundação Universitária de Cardiologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre S Quadros, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia/Fundação Universitária de Cardiologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Cardiologia/Fundação Universitária de Cardiologia (IC/FUC)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90.620-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>July 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

